The success of sirolimus - a mammalian target of rapamycin (mTOR) signaling inhibitor - in stabilizing lung function, reducing respiratory symptoms and improving quality of life in tuberous sclerosis/LAM patients is proof of concept that therapy targeting specific defective genetic and biochemical pathways can be successful [72]. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.